Loading...
•
Sep 30, 2020
Standard Biotool Q3 2020 Earnings Report
Reported a 50 percent increase in total revenue, reaching $39.9 million, and a GAAP net loss of $6.0 million.
Key Takeaways
Fluidigm Corporation announced strong third-quarter results, driven by COVID-19 testing and clinical research strategies. Total revenue increased by 50 percent to $39.9 million, with product and service revenue up 34 percent to $35.3 million. The company reported a GAAP net loss of $6.0 million and a non-GAAP net income of $2.5 million.
Total revenue increased 50 percent to $39.9 million.
Product and service revenue increased 34 percent to $35.3 million, driven by COVID-19 testing.
GAAP net loss was $6.0 million; non-GAAP net income was $2.5 million.
Cash and cash equivalents totaled $73.4 million.
Standard Biotool
Standard Biotool
Forward Guidance
The company is focused on expanding its diagnostic reach and executing on a product roadmap for microfluidics and mass cytometry to drive growth from translational and clinical research and diagnostics customer segments.